Profile picture for user var224

Vaneet Arora, MD, MPH

Connect

vaneet.arora@uky.edu
HA 620

Positions

  • Professor
  • Associate Director - Clinical Microbiology
  • Director - Kentucky State Public Health Lab

College Unit(s)

Biography and Education

Education

MBBS - University College of Medical Sciences (1993)

MD in Microbiology - University College of Medical Sciences (1999)

MPH - University of Texas (2009)

Childhood Immunizations Fellowship - University of Texas (2007)

Selected Publications

Publications & Other Scholarly Work:

1     Kumar A, Arora V, Bhushamboo A, Ali S. Detection of Salmonella typhi by polymerase chain reaction: Implications in diagnosis of typhoid fever. Infection, Genetics and Evolution. 2002 Apr; 2(2): 107-110.

2     Kaur IR, Sachdeva R, Arora V, Talwar V. Preliminary survey of leptospirosis amongst febrile patients from urban slums of east Delhi. Journal of Association of Physicians of India. 2003 Mar; 51(1): 249-251.

3     Kumar A, Arora V, Kaur IR, Talwar V. Toxoplasma antibody levels in females with habitual or sporadic abortions and normal pregnancies. Indian Journal of Medical Microbiology. 2004 Apr; 22(4): 276-277.

4     Garey KW, Jiang Z, Ghantoji S, Tam V, Arora V, DuPont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infections. Clinical Infectious Diseases. 2010:51 (15 December): 1406-1410.

5     Sethi S, Garey KW, Arora V,  Ghantoji S, Rowan P, Smolensky M, DuPont HL. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infections. Journal of Hospital Infection. 2011 Feb;77(2):172-3.

6     Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, DuPont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 2011; 66 (12): 2850-2855.

7     Halton K, Arora V, Singh V, Ghantoji S, Shah D, Garey KW. Transmission of healthcare-associated pathogens by writing pens in a clinical research setting. Clinical Microbiology and Infection. 2011; 17(6): 868–869.

8     Arora V, Kachroo S, Ghantoji SS, DuPont HL, Garey KW. Severe Horn's index predicts poor outcomes in patients with Clostridium difficile infections. Journal of Hospital Infection. 2011; 79: 23-26

9     Le F, Arora V, Shah D, Salazar M, Palmer H, DuPont HL, Garey KW. A real-world evaluation of oral vancomcyin for severe Clostridium difficile infection: Implications for antibiotic stewardship programs.  Pharmacotherapy. 2012; 32(2): 129–134

10   V Singh, V Arora, MJ Alam, and KW Garey.  Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus.  Antimicrob. Agents Chemother. 2012; 56(8): 4360-4364.

11   Arora V, Shah D, Garey KW. Overview of Clostridium difficile Infection as an Emerging Health Care Facility–Acquired Infection. Hospital Pharmacy. 2013; 48(2 Suppl-1): S1-S6

12   A.J. Fenwick, J.A. Ribes, S.L. Mills, J. Simpson, V. Arora. Luminex Verigene (Nanosphere) Blood Culture Platform Performance at UK HealthCare, Lexington, KY: June 2014 – December 2017. Abstracts and Case Studies From the College of American Pathologists 2018 Annual Meeting (CAP18). Archives of Pathology & Laboratory Medicine: September 2018, Vol. 142, No. 9, pp. e2-e202.

13   Go J, Wallace KL, Burgess DS, Burgess DR, Cotner S, Arora V. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter. Open Forum Infectious Diseases, Volume 5, Issue suppl_1, November 2018, Pages S728–S729, https://doi.org/10.1093/ofid/ofy210.2089

14   Arora V, Burgess DR, Ribes JA, Cotner S, Wallace KL, Forster D. Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel. Open Forum Infectious Diseases, Volume 5, Issue suppl_1, 26 November 2018, Pages S195-S196.

15   V. Nolt, K D Pijut, EB Autry, W C Williams, D S Burgess, D R Burgess, V. Arora, R J Kuhn.  Evaluation of Amikacin Target Achievement in Adult Cystic Fibrosis Patients Utilizing Monte Carlo Simulation. Pediatric Pulmonology. 2019;54:33-39.

16   Fenwick AJ, Arora V, Ribes J. Wohlfahrtiimonas chitiniclastica: Two Clinical Cases and a Review of the literature. Clinical Microbiology Newsletter. 2019;41 (4):33-38.

17   Jassim T, Ribes JA, Arora V. Unusual Organism—Paracoccus yeei in the United States: A Case of Surgical Wound Infection and a Case of Fatal Sepsis. Abstracts and Case Studies From the College of American Pathologists 2019 Annual Meeting (CAP19). Archives of Pathology & Laboratory Medicine: September 2019, Vol. 143, No. 9, pp. e2-e226.

18   Mediwala K, Higdon E, Arora V, Dhar S. Cirrhosis associated immune dysfunction - in the era of emerging infections and prolonged hospitalizations. Submitted: Journal of Intensive Care Medicine. March 2019

19   Go J, Wallace K, Burgess D, Arora V. "Piperacillin-Tazobactam versus Cefepime or a Carbapenem for Infections Caused by Serratia, Citrobacter, or Enterobacter". Submitted: JID, June 2019.

20   Moss J, Forster D, V Arora, JA Ribes. A Diagnostic Stewardship Intervention for Clostridiodes difficile: Impact of Stool Toxin Testing on Treatment of Adult Inpatients.  Open Forum Infectious Diseases. October 2019

21   Bhatt, M, JA Ribes, V Arora, T Myint. Clinical characteristics and outcomes of cryptococcosis in a tertiary care center in Kentucky, 2005-2017.  Open Forum Infectious Diseases. October 2019

22   Bhatt, M, JA Ribes, V Arora, T Myint. Impact of false positive, low titer cryptococcal antigen testing. Open Forum Infectious Diseases. October 2019

23   Ribes JA, Arora V, Greenberg RN. A Paradigm Shift Has Begun, Diarrheal Disease Takes a New Form, Clinical Infectious Diseases. 2019; 69(9): 1553-1554. https://doi.org/10.1093/cid/ciy1145 

24   Lin, J, T Myint, V Arora, and JA Ribes. Comparison of Yeasts identification by Biofire, Culture and ePlex for Quality Assurance purpose. Open Forum Infectious Diseases, Volume 7, Issue Supplement 1, October 2020, Page S384.

25   Rowe AD, Stoway SD, Åhlman H, Arora V, Caggana M, Fornari A, Hagar A, Hall PL, Marquardt GC, Miller BJ, Nixon C, Norgan AP, Orsini JJ, Pettersen RD, Piazza AL, Schubauer NR, Smith AC, Tang H, Tavakoli NP, Wei S, Zetterström RH, Currier RJ, Mørkrid L, Rinaldo P. A Novel Approach to Improve Newborn Screening for Congenital Hypothyroidism by Integrating Covariate-Adjusted Results of Different Tests into CLIR Customized Interpretive Tools. International Journal of Neonatal Screening. 2021; 7(2):23. https://doi.org/10.3390/ijns7020023

26   Cavanaugh AM, Fortier S, Lewis P, Arora V, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021. MMWR Morb Mortal Wkly Rep 2021;70:639-643. DOI: http://dx.doi.org/10.15585/mmwr.mm7017e2

27   Bhatt, M, JZ Porterfield, JA Ribes, V Arora, T Myint. Changing Demographics and Risk Factors for Cryptococcosis: A 12 Year Review at a Tertiary Care Center. Mycoses. 2021; 64 (9): 1073-1082. DOI: https://doi.org/10.1111/myc.13323 

Book and Book Chapters

1     Arora V. (2022) (in publication- to be released on January 14, 2022) Chapter 7: Clinical Microbiology. Gomella LG and Haist SA (Ed.), Clinician’s Pocket Reference. 12th Edition. McGraw Hill Medical. ISBN-13: 987-0-20-145428-5

2     Arora V, Garey KW. (2013) Chemotherapy of Clostridium sp Infections. Nightingale CH and Gahan C (Ed.), Encyclopedia of Pharmaceutical Microbiology. Springer. ISBN-13: 978-1441907134

3     Arora V, Arora R. (2005). General Microbiology; Bacteriology; Mycology; Virology; Parasitology; Immunology. In Arora V, Arora R (Ed.), Review of Microbiology (pp. 1-312). New Delhi, India. PEEPEE Publishers. ISBN-13: 978-8188867554